Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
AFT Leaves X Over AI-Generated Images of Minors 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
LOS ANGELES, April 03, 2017 -- Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Galena Biopharma, Inc. (“Galena” or the “Company”) (Nasdaq:GALE) concerning possible violations of federal securities laws between August 11, 2014 and January 31, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the April 14, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Galena made false and/or misleading statements and/or failed to disclose that: its sales of Abstral were based on unsustainable sales and marketing practices; that such sales and marketing practices could subject Galena to a criminal investigation; and that as a result of the above, Galena’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When this information was released to the public, shares of Galena fell in value, causing investors harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
